News & Views
Alliance Brings Ready Solution for Profiling
Jun 30 2017
An agreement between Waters Corporation and Andrew Alliance will bring drug development scientists a semi-automated sample preparation approach for released N-glycan profiling and analysis by LC and LC-MS. “With the increasing number of protein therapeutics in development, the demand for glycan analyses is growing exponentially,” said Dr. Jeff Mazzeo, Vice President, Consumables Group, Waters Corporation. “The combination of the Andrew robot with the Waters RapiFluor-MS N-Glycan Kit is an ideal solution for automating large numbers of routine, high-quality released N-glycan analyses.”
Piero Zucchelli, CEO and Founder of Andrew Alliance stated, “The Waters Glycoworks RapiFluor-MS N-Glycan Kit offers strategic and critical value that should not be compromised by the uncertainty induced by manual sample pipetting. The use of the Andrew robot for unattended execution of the kit’s sample preparation workflow addresses this point and enables scientists to make decisions based on solid and reproducible data.”
Most biotherapeutic proteins available on the market today are glycoproteins. The heterogeneous sugar molecules, or glycans, on these proteins affect the potency, stability, and therapeutic safety profiles of these drugs. As a result, biopharmaceutical companies must provide detailed structural information on these glycans when submitting new applications to regulatory authorities and must monitor them throughout the manufacturing process.
In This Edition Evaluation of Recovery of Basic Analytes Using a Mixed-Mode Strong Cation Exchange SPE Microplate by HPLC-MS The Benefits of SEC-MALLS in Biopharmaceutical Applications...
View all digital editions
Jun 28 2022 Ljubljana, Slovenia
Jul 24 2022 Chicago, IL, USA
Jul 25 2022 Virtual event
Aug 21 2022 Chicago, IL, USA & Online
Aug 22 2022 Frankfurt, Germany